$SPRB ($SPRB) is expected to release its quarterly earnings data on Monday, April 14th after market close, per Finnhub. Analysts are expecting revenue of $902,700 and ...
The average one-year price target for Spruce Biosciences (NasdaqCM:SPRB) has been revised to $137.19 / share. This is an increase of 2,045.14% from the prior estimate of $6.40 dated November 7, 2025.
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the most promising micro-cap stocks according to analysts. On February 18, Spruce Biosciences recently concluded successful Type B meetings with the FDA ...
Fintel reports that on October 21, 2025, Leerink Partners maintained coverage of Spruce Biosciences (NasdaqCM:SPRB) with a Market Perform recommendation. Analyst Price Forecast Suggests 92.13% ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Spruce Biosciences ( (SPRB)) has provided ...
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the best hot stocks to buy according to analysts. On March 9, Spruce Biosciences appointed Dale Hooks as Chief Commercial Officer to lead the company’s ...
Hong Kong-based Harbour BioMed on Sunday exercised its warrant to acquire the common stock in Spruce Biosciences Inc. (NASDAQ: SPRB). Following this transaction, Harbour BioMed holds approximately 3.8 ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results